Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.76 |
| ▸ | ITGB3 | P05106 | 17/20 | 0.76 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.57 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6910366 | 1.00 | ITGAV (0.76) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6910373 | 1.00 | ITGAV (0.76) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6792810 | 0.97 | ITGAV (0.72) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6792804 | 0.97 | ITGAV (0.72) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL5301316 | 0.88 | ITGAV (0.77) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL5301326 | 0.88 | ITGAV (0.77) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6422506 | 0.86 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6422511 | 0.86 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6359092 | 0.86 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL5301988 | 0.86 | ITGAV (0.78) | ITGAVITGB3ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGA2 | ITGAV 1/4885ITGB3 9/4885ITGB6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.